{"id":26628,"date":"2026-03-06T13:41:21","date_gmt":"2026-03-06T13:41:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/26628\/"},"modified":"2026-03-06T13:41:21","modified_gmt":"2026-03-06T13:41:21","slug":"roches-potential-blockbuster-fuels-best-month-since-1997","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/26628\/","title":{"rendered":"Roche\u2019s Potential Blockbuster Fuels Best Month Since 1997"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/ROG:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Roche Holding AG<\/a>\u2019s shares just posted their best month since 1997, lifted by optimism over an experimental <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2025-11-18\/roche-early-breast-cancer-drug-shows-edge-in-key-study\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">breast cancer<\/a> pill and encouraging trial results. Analysts see further gains ahead.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">November\u2019s 19% surge in the Swiss drugmaker\u2019s stock gained traction after Roche said its giredestrant medicine helped women with a form of early breast cancer. That followed news of two late-stage trials showing a <a href=\"https:\/\/www.bloomberg.com\/news\/articles\/2025-11-10\/roche-s-multiple-sclerosis-drug-reduced-relapses-in-two-trials\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">multiple sclerosis<\/a> drug could work for most forms of the disease.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG\u2019s shares just posted their best month since 1997, lifted by optimism over an experimental breast&hellip;\n","protected":false},"author":2,"featured_media":26629,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[2350,2112,4397,197,11448,231,304,134,13222,13826,176,3612],"class_list":{"0":"post-26628","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-astrazeneca-plc","9":"tag-cancer","10":"tag-drugs","11":"tag-europe","12":"tag-jpmorgan-chase-co","13":"tag-markets","14":"tag-pharmaceutical","15":"tag-roche","16":"tag-roche-holding-ag-genusschein","17":"tag-sp-500-index","18":"tag-stocks","19":"tag-women"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116182521166799697","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/26628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=26628"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/26628\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/26629"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=26628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=26628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=26628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}